Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The early termination of the clinical trial is due to an internal administrative and business decision, the study is not being terminated for safety reasons.

Conditions

CPVT1
Heart Defects, Congenital
Heart Diseases
Ventricular Tachycardia

Interventions

DRUG: CRD-4730
DRUG: Placebo

Sponsor

Cardurion Pharmaceuticals, Inc.